/
DCF Valuation
Base-case fair value
$9.72
Intrinsic $12.96 · 25% MOS
Current price: $6.18
Base-case summary
Our base-case DCF for Xeris Biopharma Holdings, Inc. (XERS) projects 10 years of free cash flow growth at 20.0% for years 1–5 and 10.0% for years 6–10, anchored to 69.5% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $49M in trailing free cash flow, this produces an intrinsic value of $12.96 per share. A 25% safety margin gives a fair value of $9.72, suggesting the stock is currently 57% undervalued against the $6.18 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$49M
Cash & equivalents
$112M
Total debt
$259M
Shares outstanding
178M